Design and development of heater control circuit without temperature sensor for monitoring hydrogen in argon

A thin film based tin oxide sensor is developed to monitor low levels of hydrogen (concentration ranging from 5 to 75 ppm) in the cover gas plenum of the fast breeder test reactor. The heater and the sensor patterns are integrated on a miniature alumina substrate, and necessary electrical leads are incorporated into it. For proper functioning of the sensor, the heater has to be maintained at a constant temperature of 350 °C. This paper gives an outline of the electronics developed to measure the sensor signal and to control the heater temperature.
The major challenge in this work is that there was no provision for embedding a temperature sensor on the heater surface due to physical constraints. This constrained the maintenance of a constant heater temperature for the proper functioning of the sensor. This led us to develop and demonstrate a heater control circuit without a temperature sensor to maintain a fixed temperature for https://biodas.org/ monitoring hydrogen in argon, and electronics for the above-mentioned circuitry is discussed.

ERC-ESICM guidelines on temperature control after cardiac arrest in adults

  • The aim of these guidelines is to provide evidence‑based guidance for temperature control in adults who are comatose after resuscitation from either in-hospital or out-of-hospital cardiac arrest, regardless of the underlying cardiac rhythm. These guidelines replace the recommendations on temperature management after cardiac arrest included in the 2021 post-resuscitation care guidelines co-issued by the European Resuscitation Council (ERC) and the European Society of Intensive Care Medicine (ESICM).
  • The guideline panel included thirteen international clinical experts who authored the 2021 ERC-ESICM guidelines and two methodologists who participated in the evidence review completed on behalf of the International Liaison Committee on Resuscitation (ILCOR) of whom ERC is a member society. We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence and grade recommendations. The panel provided suggestions on guideline implementation and identified priorities for future research. The certainty of evidence ranged from moderate to low.
  • In patients who remain comatose after cardiac arrest, we recommend continuous monitoring of core temperature and actively preventing fever (defined as a temperature > 37.7 °C) for at least 72 h. There was insufficient evidence to recommend for or against temperature control at 32-36 °C or early cooling after cardiac arrest. We recommend not actively rewarming comatose patients with mild hypothermia after return of spontaneous circulation (ROSC) to achieve normothermia. We recommend not using prehospital cooling with rapid infusion of large volumes of cold intravenous fluids immediately after ROSC.

Thermal Model of an Omnimagnet for Performance Assessment and Temperature Control

An Omnimagnet is an electromagnetic device that enables remote magnetic manipulation of devices such as medical implants and microrobots. It is composed of three orthogonal nested solenoids with a ferromagnetic core at the center. Electrical current within the solenoids leads to undesired temperature increase within the Omnimagnet. If the temperature exceeds the melting point of the wire insulation, device failure may occur. Thus, a study of heat transfer within an Omnimagnet is a necessity, particularly to maximize the performance of the device. A transient heat transfer model that incorporates all three heat transfer modes is proposed and experimentally validated with an average normalized root-mean-square error of less than 4% (data normalized by temperature in degree celsius). The transient model is not computationally expensive and is applicable to Omnimagnets with different structures. The code is applied to calculate the maximum safe operational time at a fixed input current or the maximum safe input current for a fixed time interval. The maximum safe operational time and maximum safe input current depend on size and structure of the Omnimagnet and the lowest critical temperature of all the Omnimagnet materials. A parametric study shows that increasing convective heat transfer during cooling, and during heating with low input currents, is an effective method to increase the maximum operational time of the Omnimagnet. The thermal model is also presented in a state-space equation format that can be used in a real-time Kalman filter current controller to avoid device failure due to excessive heating.

Integrated Temperature and Position Sensors in a Shape-Memory Driven Soft Actuator for Closed-Loop Control

Soft actuators are a promising option for the advancing fields of human-machine interaction and dexterous robots in complex environments. Shape memory alloy wire actuators can be integrated into fiber rubber composites for highly deformable structures. For autonomous, closed-loop control of such systems, additional integrated sensors are necessary. In this work, a soft actuator is presented that incorporates fiber-based actuators and sensors to monitor both deformation and temperature.
The soft actuator showed considerable deformation around two solid body joints, which was then compared to the sensor signals, and their correlation was analyzed. Both, the actuator as well as the sensor materials were processed by braiding and tailored fiber placement before molding with silicone rubber. Finally, the novel fiber-rubber composite material was used to implement closed-loop control of the actuator with a maximum error of 0.5°.

Surface temperature controls the pattern of post-earthquake landslide activity

The patterns and controls of the transient enhanced landsliding that follows strong earthquakes remain elusive. Geostatistical models can provide clues on the underlying processes by identifying relationships with a number of physical variables. These models do not typically consider thermal information, even though temperature is known to affect the hydro-mechanical behavior of geomaterials, which, in turn, controls slope stability. Here, we develop a slope unit-based multitemporal susceptibility model for the epicentral region of the 2008 Wenchuan earthquake to explore how land surface temperature (LST) relates to landslide patterns over time. 3
We find that LST can explain post-earthquake landsliding while it has no visible effect on the coseismic scene, which is dominated by the strong shaking. Specifically, as the landscape progressively recovers and landslide rates decay to pre-earthquake levels, a positive relationship between LST and landslide persistence emerges. This seems consistent with the action of healing processes, capable of restoring the thermal sensitivity of the slope material after the seismic disturbance. Although analyses in other contexts (not necessarily seismic) are warranted, we advocate for the inclusion of thermal information in geostatistical modeling as it can help form a more physically consistent picture of slope stability controls.

Stuart Temperature Controller SCT1

STI5500 Scientific Laboratory Supplies EACH 342 EUR

Heidolph Electronic Temperature Controller EKT SS Sensor

STI2100 Scientific Laboratory Supplies EACH 779.44 EUR

Eppendorf Centrifuge 5702RH temperature controlled without rotor

E5704000060 Scientific Laboratory Supplies EACH 5428.8 EUR

Eppendorf Centrifuge 5702RH temperature controlled without rotor- IVD Only

E5704000067 Scientific Laboratory Supplies EACH 5701.2 EUR

Temperature Probe 400oc

HEA5262 Scientific Laboratory Supplies EACH 453.6 EUR

Temperature Probe 800oc

HEA5264 Scientific Laboratory Supplies EACH 506.4 EUR

pH/Temperature Electrode

PHM2024 Scientific Laboratory Supplies EACH 195.6 EUR

Temperature Adjustment Set

BAL5042 Scientific Laboratory Supplies EACH 1561.2 EUR

External Temperature Probe

BLO1270 Scientific Laboratory Supplies EACH 300 EUR

External Temperature Probe

BSH-TP1 Benchmark Scientific 1 PC 228 EUR

Optional Temperature Probe

MIX1265 Scientific Laboratory Supplies EACH 183.6 EUR

Temperature probe RS600/900

HEA5518 Scientific Laboratory Supplies EACH 248.4 EUR

Agarose, Low Melt Temperature

40100156-1 Bio-WORLD 10 g 68.53 EUR

Agarose, Low Melt Temperature

40100156-2 Bio-WORLD 25 g 136.81 EUR

Agarose, Low Melt Temperature

40100156-3 Bio-WORLD 50 g 258.28 EUR

Agarose, Low Melt Temperature

40100156-4 Bio-WORLD 100 g 466.78 EUR

IKA PT1000.70 Temperature Probe

STI2837 Scientific Laboratory Supplies EACH 231.6 EUR

pt1000 temperature compensator

ST10N Consort ea 112.8 EUR

pt1000 temperature compensator

ST20N Consort ea 117.6 EUR

Hanna Temperature Probe+Cable

PHM4124 Scientific Laboratory Supplies EACH 122.4 EUR

Temperature probe for compost

THE0810 Scientific Laboratory Supplies EACH 162 EUR

Temperature Datalogger(EBI 300)

THE1846 Scientific Laboratory Supplies EACH 113.59 EUR

An overview of different homogenizers, their working mechanisms and impact on processing of fruits and vegetables

Fruits and vegetables (F&V) are the second highest recommended foods, rich in antioxidants, vitamins and minerals, vital for building immunity against chronic diseases. F&V processing involves particle size reduction, for which different types of homogenizers, categorized as mechanical homogenizers, pressure homogenizers and ultrasonic homogenizers are used. The review discusses different types of homogenizers, their working mechanism, and application in F&V processing. Among mechanical homogenizers, knife mills are used for primary size reduction, ball mills for the micronization of dried F&V and rotor-stator homogenizers for emulsification.
Use of the ultrasonic homogenizer is limited to extraction of bioactive compounds or as a pre-treatment for dehydration of F&V. High-pressure homogenizers are most widely used and reported due to the synergistic effect of homogenization and temperature increase, resulting in longer shelf-life and better physicochemical properties of the product. Additionally, the review also explains the effect of homogenization on the physicochemical, sensory and https://biodas.org/ nutraceutical properties of the product.

Pre-processing tissue specimens with a tissue homogenizer: clinical and microbiological evaluation

Background: Tissues are valuable specimens in diagnostic microbiology because they are often obtained by invasive methods, and effort should thus be taken to maximize microbiological yield. The objective of this study was to evaluate the added value of using tissue pre-processing (tissue homogenizer instrument gentleMACS Dissociator) in detecting microorganisms responsible for infections.
Methods: We included 104 randomly collected tissue samples, 41 (39.4 %) bones and 63 (60.6 %) soft tissues, many of those (42/104 (40.4 %)) were of periprosthetic origins. We compared the agreement between pre-processing tissues using tissue homogenizer with routine microbiology diagnostic procedure, and we calculated the performance of these methods when clinical infections were used as reference standard.
Results: There was no significant difference between the two methods (McNemar test, p = 0.3). Among the positive culture using both methods (n = 62), 61 (98.4 %) showed at least one similar microorganism. Exactly similar microorganisms were found in 42/62 (67.7 %) of the samples. From the included tissues, 55/ 104 (52.9 %) were deemed as infected. We found that the sensitivity of homogenized tissue procedure was lower (83.6 %) than when tissue was processed using tissue homogenizer (89.1 %). Sub-analysis on periprosthetic tissues and soft or bone tissues showed comparable results.
Conclusions: The added value of GentleMACS Dissociator tissue homogenizer is limited in comparison to routine tissue processing.

Functionality of MC88- and MPC85-Enriched Skim Milk: Impact of Shear Conditions in Rotor/Stator Systems and High-Pressure Homogenizers on Powder Solubility and Rennet Gelation Behavior

  • Milk protein concentrate (MPC) and micellar casein (MC) powders are commonly used to increase the protein concentration of cheese milk. However, highly-concentrated milk protein powders are challenging in terms of solubility. The research question was whether and how incompletely dissolved agglomerates affect the protein functionality in terms of rennet gelation behavior. For the experiments, skim milk was enriched with either MC88 or MPC85 to a casein concentration of 4.5% (w/w) and sheared on a laboratory and pilot scale in rotor/stator systems (colloid mill and shear pump, respectively) and high-pressure homogenizers.
  • The assessment criteria were on the one hand particle sizes as a function of shear rate, and on the other hand, the rennet gelation properties meaning gelling time, gel strength, structure loss upon deformation, and serum loss. Furthermore, the casein, whey protein, and casein macropeptide (CMP) recovery in the sweet whey was determined to evaluate the shear-, and hence, the particle size-dependent protein accessibility. We showed that insufficient powder rehydration prolongs the rennet gelation time, leading to softer, weaker gels, and to lower amounts of CMP and whey protein in the sweet whey.

Characterization of Astaxanthin Nanoemulsions Produced by Intense Fluid Shear through a Self-Throttling Nanometer Range Annular Orifice Valve-Based High-Pressure Homogenizer

Stable, oil-in-water nanoemulsions containing astaxanthin (AsX) were produced by intense fluid shear forces resulting from pumping a coarse reagent emulsion through a self-throttling annular gap valve at 300 MPa. Compared to crude emulsions prepared by conventional homogenization, a size reduction of over two orders of magnitude was observed for AsX-encapsulated oil droplets following just one pass through the annular valve. In krill oil formulations, the mean hydrodynamic diameter of lipid particles was reduced to 60 nm after only two passes through the valve and reached a minimal size of 24 nm after eight passes.
Repeated processing of samples through the valve progressively decreased lipid particle size, with an inflection in the rate of particle size reduction generally observed after 2-4 passes. Krill- and argan oil-based nanoemulsions were produced using an Ultra Shear Technology™ (UST™) approach and characterized in terms of their small particle size, low polydispersity, and stability.

Characteristics of an Emulsion Obtained Using Hydrophobic Hydroxypropyl Methylcellulose as an Emulsifier and a High-Pressure Homogenizer

Hydrophobically modified hydroxypropyl methylcellulose (HM-HPMC), a polymer in which a small amount of HPMC is stearoxyl substituted, was used as an emulsifier of emulsion-type lotion. A high-pressure homogenizer (microfluidizer) was used. The viscosity of the 1% HM-HPMC aqueous gel decreased after passing through the microfluidizer from 5.5 to 2.7 Pa·s. When liquid paraffin (LP) was used as the oil phase, a stable emulsion was obtained with an LP ratio of 1-40%. The apparent viscosity decreased with LP ratios up to 20%, and then increased with increasing LP concentration.
The emulsions with an LP ratio <20% presented a pseudo-viscous flow, similar to that of the diluted polymer solution. HM-HPMC likely adsorbed onto the oil with a stearoxyl group; thus, the interaction between the stearoxyl group, which explained the high viscosity of HM-HPMC, decreased, reducing the viscosity of the emulsion. The LP ratio was 40%, and the emulsion presented a plastic flow, which is typical of concentrated emulsions. The size of the droplet in the emulsion was approximately 1 µm regardless of the LP ratio. When low-viscosity LPs or monoester-type oils such as isopropyl myristate were used, some of the emulsions presented creaming. An emulsion using HM-HPMC as an emulsifier and an appropriate oil homogenized with a microfluidizer is stable, has low viscosity, and can be easily spread on skin.

Proteomic evaluation of plasma membrane fraction prepared from mouse liver and kidney using a bead homogenizer: Enrichment of drug-related transporter proteins

Quantifying the protein levels of drug transporters in plasma membrane fraction helps elucidate the function of these transporters. In this study, we conducted a proteomic evaluation of enriched drug-related transporter proteins in plasma membrane fraction prepared from mouse liver and kidney tissues using the Membrane Protein Extraction Kit and a bead homogenizer. Crude and plasma membrane fractions were prepared using either the Dounce or bead homogenizer, and protein levels were determined using quantitative proteomics.
In liver tissues, the plasma membrane fractions were more enriched in transporter proteins than the crude membrane fractions; the average enrichment ratios of plasma-to-crude membrane fractions were 3.31 and 6.93 using the Dounce and bead homogenizers, respectively. The concentrations of transporter proteins in plasma membrane fractions determined using the bead homogenizer were higher than those determined using the Dounce homogenizer. Meanwhile, in kidney tissues, the plasma membrane fractions were enriched in transporters localized in the brush-border membrane to the same degree for both the homogenizers; however, the membrane fractions obtained using either homogenizer were not enriched in Na+/K+-ATPase and transporters localized in the basolateral membrane. These results indicate that fractionation, using the bead homogenizer, yielded transporter-enriched plasma membrane fractions from mouse liver and kidney tissues; however, no enrichment of basolateral transporters was observed in plasma membrane fractions prepared from kidney tissues.

BeadBug™ Microtube homogenizer, 115V

D1030 Benchmark Scientific 1 each 980.8 EUR

BeadBug™ Microtube homogenizer, 230V

D1030-E Benchmark Scientific 1 PC 980.8 EUR

BeadBug 6, Six Position Homogenizer, 115V

D1036 Benchmark Scientific 1 each 2617.7 EUR

BeadBug 6, Six Position Homogenizer, 230V

D1036-E Benchmark Scientific 1 PC 2617.7 EUR

BeadBug 6 Six Position Homogenizer 230V

HOM3018 Scientific Laboratory Supplies EACH 3400.8 EUR

BeadBlaster™ Microtube homogenizer, 115V

D2400 Benchmark Scientific 1 each 9275.1 EUR

BeadBlaster™ Microtube homogenizer, 230V

D2400-E Benchmark Scientific 1 PC 9275.1 EUR

BeadBlaster Microtube homogenizer 230V

HOM3012 Scientific Laboratory Supplies EACH 12158.4 EUR

BeadBug Microtube homogenizer

SLS1402 Scientific Laboratory Supplies EACH 1448.4 EUR

BeadBlaster™ 24 Refrigerated Microtube Homogenizer, 115V

D2400-R Benchmark Scientific 1 each 14802.1 EUR

BeadBlaster™ 24 Refrigerated Microtube Homogenizer, 230V

D2400-R-E Benchmark Scientific 1 each 14802.1 EUR

BeadBlaster 24 Refrigerated Microtube Homogenizer 230V

HOM3078 Scientific Laboratory Supplies EACH 22038 EUR

Homogenizer stand for Agile? Hand-held homogenizer

AHM1-VS ACTGene each 634.8 EUR

Homogenizer stand for Agile™ Hand-held homogenizer

AHM1 ACTGene VS 414.21 EUR

Microtube homogenizer, 115V

BCM1200 Bio Basic 1 pcs, 1 UNIT 11944.61 EUR

Microtube homogenizer, 115V

BCM1201 Bio Basic 1 pcs, 1 UNIT 1224.14 EUR

Dounce Tissue Homogenizer

1998-1 Biovision each 470.4 EUR

Pulse 150 Ultrasonic Homogenizer

HOM3082 Scientific Laboratory Supplies EACH 3891.6 EUR

D1000 Homogenizer incl 5mm and 7mm generators 230V

HOM3064 Scientific Laboratory Supplies EACH 1689.6 EUR

Pulse 150™ Ultrasonic Homogenizer with 6mm horn and soundproof box, 120V

DP0150 Benchmark Scientific 1 each 3428.4 EUR

Scalable and Robust Bacterial Cellulose Carbon Aerogels as Reusable Absorbents for High-Efficiency Oil/Water Separation

Efficient selective separation of oils or organic pollutants from water is important for ecological, environmental conservation and sustainable development. Various absorption methods have emerged; the majority of them still suffer from defects including low removal efficiency, a complicated preparation process, and high cost. Herein, we present a highly porous and mechanical resilient bacterial cellulose (BC) carbon aerogel directly from BC hydrogel via facile directional freeze-drying and high-temperature carbonization. The resultant BC carbon aerogel showed excellent mechanical compressibility (maximal height compression ∼99.5%) and elastic recovery due to the porous structure. Taking advantages of the high thermal stability and superhydrophobicity, the BC carbon aerogel was directly used as a versatile adsorbent for oil/water separation.
The result demonstrated that the BC carbon aerogel showed super oil/water separation selectivity with the oil absorption capacity as high as 132-274 g g-1. More importantly, the BC carbon aerogel adsorbent can be reused by a simple absorption/combustion method and still keep high-efficiency oil absorption capacity and excellent superhydrophobicity after 20 absorption/combustion cycles, displaying recyclability and robust stability. In sum, the BC carbon aerogel introduced here is easy to fabricate, ecofriendly, highly scalable, low cost, mechanically robust, and reusable; https://biodas.org/ all of these features make it highly attractive for oil/water separation application.

A camphene-camphor-polymer composite material for the production of superhydrophobic absorbent microporous foams

In a recently published paper (doi.org/10.3390/molecules26113116) on self-propelled motion of objects on the water surface, we described a novel surface-active plastic material obtained by dissolution of camphor and polypropylene in camphene at 250 [Formula: see text]C. The material has wax-like mechanical properties, can be easily formed to any moldable shape, and allows for longer and more stable self-propelled motion if compared with pure camphor or pure camphene or of a camphene-camphor wax.
Here we use scanning electron microscopy to visualize and characterize the microporous structure of the solid polypropylene foam formed in the plastic for different polypropylene contents. The topology of foams remaining in the material after camphor and camphene molecules have been removed through evaporation or dissolution is similar to polypropylene foams obtained using thermally-induced phase separation. We show that the foams have a superhydrophobic surface but strongly absorb non-polar liquids, and suggest an array of potential scientific and industrial applications.

Development of pH-responsive absorbent pad based on polyvinyl alcohol/agarose/anthocyanins for meat packaging and freshness indication

Absorbent pads with antioxidant and pH-responsive color changing functions have been developed based on polyvinyl alcohol (PVA), agarose (AG), and purple sweet potato anthocyanins (PSPA), aiming for fresh keeping and freshness indication of fresh meat. The effects of PSPA content on the structure, physical properties, and colorimetric response towards pH changing of pads were evaluated. The results showed that PSPA interacted with PVA and AG and influenced the crystallinity, thermal stability and micro-morphology of pads.
The increase of the PSPA content from 3% to 12% improved the strength and DPPH radical scavenging activity of the pads, but reduced the swelling ratio. Significant color change of the pads was observed when pH increased from 3 to 10, and the pad containing 9% PSPA presented the most distinguishable color change with the change of pH. When applied as an absorbent pad for minced meat packaging, the pad indicated the real-time spoilage of the meat through obvious color change, and also extended the shelf life by at least 24 h. Therefore, the dual-functional pad shows great potential to be applied as a smart and active packaging for fresh meat, which would play an important role in ensuring food safety and improving food storage quality.

Occurrence and distribution of organic ultraviolet absorbents in sediments from small urban rivers, Tianjin, China: Implications for risk management

Organic ultraviolet absorbents (OUVAs) in the environment have been of increasing concern because of their potential hazards. However, the OUVAs in waters is far from being well studied and little is known about their occurrence in small urban rivers. This study investigated the concentrations and distribution of eleven OUVAs in the sediments from five small urban rivers of Tianjin, China, and found total concentrations in the range of 11.6-189 ng/g dry weight. Relative to other rivers and lakes, no high concentrations of sediment OUVAs were observed in the small rivers. Benzophenone, homosalate and octocrylene were the dominant OUVAs, representing medians of 13.3%, 12.4% and 12.3% of the total concentrations, respectively.
Our observed composition profiles of these chemicals were different from those found in most of other waters. The sediment OUVAs may originate more from industrial activities than the use of cosmetics and personal care products in this area. The risk to aquatic organisms from exposure to the sediment OUVAs in these small urban rivers was considered low, except for benzophenone. However, more researches are needed to investigate the pollution and associated risks of these chemicals in urban rivers due to the complexity of their toxicity to aquatic organisms.

Mixture Compound Fertilizer and Super Absorbent Polymer Application Significantly Promoted Growth and Increased Nutrient Levels in Pinus massoniana Seedlings and Soil in Seriously Eroded Degradation Region of Southern China

  • Pinus massoniana is the pioneer tree species in the red soil regions of southern China, however, the serious understory soil erosion and nutrient deficiency in that region are the main factors restricting the growth of P. massoniana. This field study examined the effects of compound fertilizer and super absorbent polymer (SAP) on the physiology, growth characteristics, biomass, soil nutrient, plant nutrient content, and nutrient uptake efficiency of 1-year-old P. massoniana seedlings for 2 years at Changting, Fujian in South China. One control (no fertilizer, CK) and fertilization treatments were established, namely, single compound fertilizer application (0.94, 1.89, and 3.56 g⋅plant-1) and mixture compound fertilizer and SAP application (0.94 + 1.01, 1.89 + 1.01, and 3.56 + 1.01 g⋅plant-1).
  • Fertilization significantly improved the physiological performance, root collar diameter growth, height growth, biomass, and nutrient uptake of the seedlings. Compared with other fertilization treatments, the mixture compound fertilizer and SAP application significantly improved the seedling photosynthesis, which meant that the SAP had a significant effect on promoting photosynthesis. Under the mixture compound fertilizer and SAP application, the whole biomass of the seedlings was higher than that of all other treatments. Fertilization significantly increased the nitrogen (N), phosphorus (P), and potassium (K) content in the soils, leaves, stems, and roots of the seedlings, respectively.
  • The P content was the main factor affecting growth characteristics and contributed to 58.03% of the total variation in seedling growth characteristics (P < 0.01). The N:P ratio of CK in the soils, leaves, and stems were higher than that of all the fertilization treatments, indicating that the severely eroded and degraded region had little P and required much of P. The principal component analysis indicated that the F2S (1.89 + 1.01 g) was the optimum fertilization amount and method in this experiment. These results provide a theoretical basis for the fertilization management of P. massoniana forests with severely eroded and degraded red soil regions.

Absorbent paper roll

DD30640 Scientific Laboratory Supplies EACH 25.2 EUR

Cotton Wool White Absorbent 500g

COT1000 Scientific Laboratory Supplies EACH 28.46 EUR

Human anti-Mouse Antibody Absorbent (HAMA)

HAMA Alpha Diagnostics 1 gram 343.2 EUR

Chemical Absorbent Pads 50cm x 40cm Yellow

SAF3730 Scientific Laboratory Supplies PK100 121.42 EUR

Maintenance Absorbent Roll 50cm x 40m Grey

SAF3750 Scientific Laboratory Supplies EACH 120.12 EUR

Absorbent Chemical Spill Response Kit 15L Clip-Top Bag

SAF3722 Scientific Laboratory Supplies EACH 54.05 EUR

Absorbent Chemical Spill Response Kit 20L Clip-Top Bag

SAF3724 Scientific Laboratory Supplies EACH 56.92 EUR

RF Absorbent for the removal of IgG in human plasma/serum

RF-ABS Alpha Diagnostics 100 tests 270 EUR

Absorbent Chemical Spill Response Kit 80L Circular Static Bin

SAF3716 Scientific Laboratory Supplies EACH 157.98 EUR

Cryo Express Dry Shipper with replaceable absorbent Material (CXR100)

TW-CXR100 MiTeGen 1 SHIPPER 1365 EUR

S. Pneumococcal CWPS/22F Absorbent solution for removing/adsorbing non-specific CWPS/22F from human or animal samples (sufficient for 50 samples)

560-CW-ABS Alpha Diagnostics 1 vial 416.4 EUR

100ml absorbency pad

SCIEA08 Scientific Laboratory Supplies PK500 117.42 EUR

A6 95kPa Specimen Transport Pouch with 20mL Absorbency Pad

COV1138 Scientific Laboratory Supplies PK1000 1279.49 EUR

A5 Specimen bag with Document Pouch Inserted 20ml absorbency

COV1147 Scientific Laboratory Supplies PK500 378.62 EUR

450ML Carbamate-1 CO2 Absorber

NAT1386 Scientific Laboratory Supplies 450ML 91.2 EUR

Goat anti-Mouse IgG(H+L) Cross absorbed against human immunoglobulins

E16SPU1011-100 EnoGene 100µg 286.8 EUR

Goat anti-Mouse IgG(H+L) Cross absorbed against human immunoglobulins

E16SPU1011-1000 EnoGene 1000µg 520.8 EUR

Goat anti-Mouse IgG(H+L) Cross absorbed against human immunoglobulins

E16SPU1011-500 EnoGene 500µg 411.6 EUR

Goat anti-Rabbit IgG(H+L) Cross absorbed against human immunoglobulins

E16SPU1021-100 EnoGene 100µg 286.8 EUR

Goat anti-Rabbit IgG(H+L) Cross absorbed against human immunoglobulins

E16SPU1021-1000 EnoGene 1000µg 520.8 EUR

Goat anti-Rabbit IgG(H+L) Cross absorbed against human immunoglobulins

E16SPU1021-500 EnoGene 500µg 411.6 EUR

Goat anti-Human IgG(H+L) Cross absorbed against mouse immunoglobulins

E16SPU1031-100 EnoGene 100µg 286.8 EUR

Mutations in the receptor-binding domain of human SARS CoV-2 spike protein increases its affinity to bind human ACE-2 receptor

The severe acute respiratory syndrome virus-2 (SARS CoV-2) infection has resulted in the current global pandemic. The binding of SARS CoV-2 spike protein receptor-binding domain (RBD) to the human angiotensin converting enzyme-2 (ACE-2) receptor causes the host infection. The spike protein has undergone several mutations with reference to the initial strain isolated during December 2019 from Wuhan, China. A number of these mutant strains have been reported as variants of concern and as variants being monitored. Some of these mutants are known to be responsible for increased transmissibility of the virus.
The reason for the increased transmissibility caused by the point mutations can be understood by studying the structural implications and inter-molecular interactions in the binding of viral spike protein RBD and human ACE-2. Here, we use the crystal structure of the RBD in complex with ACE-2 available in www.joplink.net/coronavirus-proteins/ the public domain and analyse the 250 ns molecular dynamics (MD) simulations of wild-type and mutants; K417N, K417T, N440K, N501Y, L452R, T478K, E484K and S494P.
The ionic, hydrophobic and hydrogen bond interactions, amino acid residue flexibility, binding energies and structural variations are characterized. The MD simulations provide clues to the molecular mechanisms of ACE-2 receptor binding in wild-type and mutant complexes. The mutant spike proteins RBD were associated with greater binding affinity with ACE-2 receptor. Communicated by Ramaswamy H. Sarma.

COVID-19 and Alzheimer’s disease: Meninges-mediated neuropathology

SARS-CoV-2 the causative agent of COVID-19 displays a broad range of pathophysiology. Cytokine storms associated with COVID-19 damage the blood-brain barrier (BBB) and allow pro-inflammatory factors to invade the brain, further promoting neurodegeneration. While SARS-CoV-2 viral RNA and proteins have been detected in brain tissues, the mechanisms of neuroinvasion remain unknown. COVID-19 has had a disproportionate impact on those suffering from neurodegenerative disorders such as Alzheimer’s disease (AD).
Understanding the mechanisms of SARS-CoV-2 neuroinvasion is crucial to study the long-term neurocognitive effects of COVID-19 on AD pathology.
Viruses can infiltrate the brain through the meninges via infected immune cells. The meninges regulate the immune surveillance of the brain and play a key role in the efflux of pathogens from the brain. Meningeal dysfunction has been demonstrated to exacerbate amyloid-beta pathogenesis. In this study, we explore the neuroinvasion pathway of SARS-CoV-2 through the meninges and its effect on AD pathology.
Method: 5x FAD x hACE2 mice were inoculated intranasally with a sublethal dose of SARS-CoV-2. The mice were maintained for 2 weeks. Mouse brains and meninges were harvested. The tissue was stained and immunofluorescence imaging was conducted to study viral proliferation and immune responses. Histo-cytometry was conducted for quantitative imaging analysis. Gene expression studies were done using Nanostring assays. All experiments involving the SARS-Cov-2 virus were carried out in a BSL3 facility.
Result: This ongoing study demonstrates the proliferation of the SARS-CoV-2 virus in the brain via meningeal lymphatics. SARS-CoV-2 infection resulted in increased neuroinflammation. Additionally, inflammatory responses induced meningeal dysfunction resulting in increased amyloid-beta pathology and cerebrospinal fluid drainage.
Conclusion: Given the increasing evidence for a viral hypothesis of Alzheimer’s Disease it is extremely important to study the neurodegenerative effects of COVID-19 which has affected millions worldwide. We demonstrate that SARS-CoV-2 infiltrates the brain via the meninges promoting neuroinflammation. Furthermore, amyloid-beta pathologies are exacerbated by COVID-19 in animal models providing preclinical evidence of the long-term neurodegenerative effects of COVID-19.

Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by beta-coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has rapidly spread across the globe starting from February 2020. It is well established that during viral infection, extracellular vesicles become delivery/presenting vectors of viral material. However, studies regarding extracellular vesicle function in COVID-19 pathology are still scanty. Here, we performed a comparative study on exosomes recovered from the plasma of either MILD or SEVERE COVID-19 patients.
We show that although both types of vesicles efficiently display SARS-CoV-2 spike-derived peptides and carry immunomodulatory molecules, only those of MILD patients are capable of efficiently regulating antigen-specific CD4+ T-cell responses. Accordingly, by mass spectrometry, we show that the proteome of exosomes of MILD patients correlates with a proper functioning of the immune system, while that of SEVERE patients is associated with increased and chronic inflammation.
Overall, we show that exosomes recovered from the plasma of COVID-19 patients possess SARS-CoV-2-derived protein material, have an active role in enhancing the immune response, and possess a cargo that reflects the pathological state of patients in the acute phase of the disease.

Role of SARS-CoV-2 in causing blood-brain barrier leakage and microglial activation as a risk factor of cognitive deterioration in subjects at risk of Alzheimer’s disease

The recent pandemic provides evidence of altered central nervous system (CNS) function in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-COV-2 invades the CNS by binding angiotensin-converting enzyme 2 (ACE2) expressed on neurons and glia. SARS-COV-2 may have effects on increased permeability of endothelial cells within the blood-brain barrier (BBB) as studies have shown that the S1 protein can transverse the BBB.
This is interesting because leakage of the BBB is implicated in Alzheimer’s disease (AD) pathogenesis. We hypothesized that SARS-CoV-2 infection leads to innate stimulated inflammation, ultimately activating microglial cells and an influx of pro-inflammatory cytokines and leukocytes in the meninges, contributing to increased permeability of the BBB. This BBB permeability increases AD susceptibility in subjects at risk by causing irreversible damage to the BBB and microglial cell activation.
Method: We developed a double transgenic mouse model using mice expressing human ACE2 receptor and 5xFAD mice that exhibit increased neuropathology seen in human AD allowing modeling of AD in SARS-CoV-2 pathogenesis. The hACE2/5xFAD double transgenic mice were intranasally inoculated with a sub-lethal dose of SARS-CoV-2 to test the hypothesis that SARS-COV-2 potentiates AD pathology and cognitive deterioration through impairment of the BBB. Leukocyte and cytokine populations were measured by flow cytometry and single-nuclei RNA sequencing of the meninges for characterization of microglial populations.
Result: SARS-CoV-2 creates a cytotoxic environment in the brain immediately following infection in hACE2/5xFAD mice leading to leakage of the BBB in the meninges. Activation of microglial innate cells by SARS-COV-2 invasion of the CNS will cause neural deterioration having long term implications on cognitive function. The hACE2/5xFAD mouse model allows us to uncover implications for SARS-COV-2 on AD cognitive deterioration.
Conclusion: The hACE2/5xFAD mouse allows modeling of SARS-CoV-2 in developing AD cases and allowed us to determine the immune environment generated in the meninges in response to SARS-CoV-2 infections. This mouse model provides a platform to proactively determine the effects of SARS-CoV-2 in developing AD cases, a methodology to be exploited for future mouse models determining the relationship of other viruses on AD pathology, and the opportunity to address phenotypes with therapeutics for preventative initiatives.

Recombinant SARS SARS MERS Protein, His, E.coli-1mg

1mg 1513.2 EUR

Recombinant SARS SARS-CoV Protein, His, E.coli-1mg

1mg 4744.8 EUR

Recombinant SARS SARS-CoV Protein, His, E.coli-5ug

5ug 186 EUR

Recombinant SARS SARS MERS Protein, His, E.coli-100ug

100ug 261.6 EUR

Recombinant SARS SARS MERS Protein, His, E.coli-500ug

500ug 795.6 EUR

Recombinant SARS SARS-CoV Protein, His, E.coli-20ug

20ug 241.2 EUR

Recombinant SARS SARS Spike S1 Protein, Avi His Tag

20ug 495 EUR

Recombinant SARS SARS Spike RBD Protein, Avi His Tag

20ug 495 EUR

Recombinant SARS SARS Core Protein, Untagged, E.coli-1mg

1mg 1273.2 EUR

Recombinant SARS SARS Core Protein, Untagged, E.coli-1mg

1mg 1273.2 EUR

The ZT Biopolymer: A Self-Assembling Protein Scaffold for Stem Cell Applications.

The ZT Biopolymer: A Self-Assembling Protein Scaffold for Stem Cell Applications.

The event of cell tradition programs for the naturalistic propagation, self-renewal and differentiation of cells ex vivo is a excessive purpose of molecular engineering. Regardless of vital success in recent times, the excessive value of up-scaling cultures, the necessity for xeno-free tradition situations, and the diploma of mimicry of the natural extracellular matrix attainable in vitro utilizing designer substrates proceed to pose obstacles to the interpretation of cell-based technologies.

On this regard, the ZT biopolymer is a protein-based, steady, scalable, and economical cell substrate of excessive promise. ZT relies on the naturally occurring meeting of two human proteins: titin-Z1Z2 and telethonin. These protein constructing blocks are strong scaffolds that may be conveniently functionalized with full-length proteins and bioactive peptidic motifs by genetic manipulation, previous to self-assembly.

The polymer is, thereby, totally encodable. Functionalized variations of the ZT polymer have been proven to efficiently maintain the long-term culturing of human embryonic stem cells (hESCs), human induced pluripotent stem cells (hiPSCs), and murine mesenchymal stromal cells (mMSCs).

Pluripotency of hESCs and hiPSCs was retained for the longest interval assayed (four months). Outcomes level to the big potential of the ZT system for the creation of a modular, pluri-functional biomaterial for cell-based purposes.

The ZT Biopolymer: A Self-Assembling Protein Scaffold for Stem Cell Applications.

Maxwell®: An Unsupervised Studying Method for 5P Medication.

Within the 5P medication (Customized, Preventive, Participative, Predictive and Pluri-expert), the final pattern is to course of information by displacing the barycenter of the data from hospital centered programs to the affected person centered ones by his private medical information.

EGF

90201-3 1000 µg
EUR 335
Description: Human Epidermal Growth Factor (GenBank Accession No. NM_001963), a.a. 971- 1023, MW=6.2 kDa, expressed in an E. coli expression system.

EGF

MO15063 100 ug
EUR 490.8

EGF

LF-PR003 200 ug
EUR 170.4
Description: EGF protein

EGF

PR27006 500 ug
EUR 381.6

EGF

PR27009 500 ug
EUR 381.6

EGF

E13-007-1 10μg
EUR 99.6

EGF

E13-007-2 50μg
EUR 138

EGF

E21-029 10ug
EUR 411.6

EGF

E8ET1704-33 100ul
EUR 275
Description: Available in various conjugation types.

EGF

cyt-217 100µg
EUR 60
Description: Recombinant Human Epidermal Growth Factor

EGF

ant-169 0.5mg
EUR 275
Description: Mouse Anti Human Epidermal Growth Factor

rHu EGF

AK8327-0100 100µg Ask for price

rHu EGF

AK8327-0500 500µg Ask for price

rHu EGF

AK8327-1000 1mg Ask for price

EGF, Rat

HY-P7092 50ug
EUR 253.2

EGF Long

cyt-798 20µg
EUR 60
Description: Recombinant Human Epidermal Growth Factor Long

EGF siRNA

20-abx915073
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

EGF siRNA

20-abx915074
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

EGF siRNA

20-abx901657
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

Mouse EGF

90200-1 100 µg
EUR 85
Description: Mouse Epidermal Growth Factor (GenBank Accession No. NM_010113), a.a. 977- 1029, MW=6.0 kDa, expressed in an E. coli expression system.

Mouse EGF

90200-2 500 µg_x000D_
EUR 210
Description: Mouse Epidermal Growth Factor (GenBank Accession No. NM_010113), a.a. 977- 1029, MW=6.0 kDa, expressed in an E. coli expression system.

Mouse EGF

90200-3 1000 µg
EUR 320
Description: Mouse Epidermal Growth Factor (GenBank Accession No. NM_010113), a.a. 977- 1029, MW=6.0 kDa, expressed in an E. coli expression system.

EGF Mouse

P2558-.1 100 µg
EUR 129.6

EGF Mouse

P2558-.5 500 µg
EUR 240

EGF Mouse

P2558-1 1 mg
EUR 373.2

EGF, Mouse

HY-P7067 100ug
EUR 224.4

EGF, Human

HY-P7109 50ug
EUR 129.6

EGF, Human

E34M120-100HP 100 μg
EUR 155

EGF,Swine

E34M018S 5 μg
EUR 295

EGF,Mouse

E34M065M 100 μg
EUR 155

EGF Pichia

PR27007 500 ug
EUR 381.6

EGF, Pichia

cyt-332 100µg
EUR 60
Description: Recombinant Human Epidermal Growth Factor, Pichia

EGF Protein

abx169012-1mg 1 mg
EUR 543.6

EGF protein

30R-1056 100 ug
EUR 321.6
Description: Purified recombinant Human EGF protein

EGF protein

30R-2331 500 ug
EUR 380.4
Description: Purified recombinant Human EGF protein

EGF protein

30R-2332 500 ug
EUR 390
Description: Purified recombinant Mouse EGF protein

EGF protein

30R-2333 20 ug
EUR 252
Description: Purified recombinant Rat EGF protein

EGF protein

30R-AE003 1 mg
EUR 457.2
Description: Purified recombinant Human EGF protein

EGF protein

30R-AE004 100 ug
EUR 159.6
Description: Purified recombinant Human EGF protein

EGF protein

30R-AE025 100 ug
EUR 327.6
Description: Purified recombinant Human EGF protein

EGF Protein

abx069820-1mg 1 mg
EUR 1296

EGF antibody

10-E39A 500 ug
EUR 679.2
Description: Mouse monoclonal EGF antibody

EGF antibody

10R-2038 100 ul
EUR 483.6
Description: Mouse monoclonal EGF antibody

EGF antibody

10R-2176 100 ul
EUR 483.6
Description: Mouse monoclonal EGF antibody

EGF antibody

10R-2969 100 ug
EUR 318
Description: Mouse monoclonal EGF antibody

EGF antibody

10R-2985 100 ug
EUR 318
Description: Mouse monoclonal EGF antibody

EGF antibody

10R-7766 500 ug
EUR 678
Description: Mouse monoclonal EGF antibody

EGF antibody

20C-CR1085GP 100 ug
EUR 177.6
Description: Goat polyclonal EGF antibody

EGF antibody

20R-1772 100 ug
EUR 807.6
Description: Rabbit polyclonal EGF antibody

EGF Antibody

BF0066 200ul
EUR 540

EGF antibody

38447-100ul 100ul
EUR 302.4

EGF antibody

70R-EG001 50 ug
EUR 327.6
Description: Affinity purified Goat polyclonal EGF antibody

EGF antibody

70R-ER012 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal EGF antibody

EGF antibody

70-ER40 50 ug
EUR 340.8
Description: Affinity purified Rabbit polyclonal EGF antibody

EGF Antibody

49545-100ul 100ul
EUR 399.6

EGF Antibody

49545-50ul 50ul
EUR 286.8

EGF antibody

70R-12248 100 ug
EUR 483.6
Description: Rabbit polyclonal EGF antibody

EGF antibody

70R-12249 100 ug
EUR 483.6
Description: Rabbit polyclonal EGF antibody

EGF antibody

70R-13940 100 ug
EUR 386.4
Description: Affinity purified Goat polyclonal EGF antibody

EGF antibody

70R-15294 100 ug
EUR 392.4
Description: Rabbit polyclonal EGF antibody

EGF antibody

70R-5697 50 ug
EUR 560.4
Description: Rabbit polyclonal EGF antibody

EGF Antibody

35720-100ul 100ul
EUR 302.4

EGF Antibody

5022-100 each
EUR 379.2

EGF Antibody

5022-30T each
EUR 175.2

EGF Antibody

5023R-100 each
EUR 379.2

EGF Antibody

5023R-30T each
EUR 175.2

EGF Antibody

ABD2225 100 ug
EUR 525.6

EGF Antibody

ABF5148 100 ug
EUR 525.6

EGF Antibody

ABD7063 100 ug
EUR 525.6

EGF Antibody

DF2225 200ul
EUR 420

EGF Antibody

1-CSB-PA06244A0Rb
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against EGF. Recognizes EGF from Human. This antibody is Unconjugated. Tested in the following application: ELISA

egf Antibody

1-CSB-PA24449A0Rb
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against egf. Recognizes egf from Zebrafish. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000

EGF Antibody

1-CSB-PA846755
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against EGF. Recognizes EGF from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100

EGF Antibody

1-CSB-PA942209
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against EGF. Recognizes EGF from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:50-1:200

EGF Antibody

1-CSB-PA007939
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against EGF. Recognizes EGF from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/10000

EGF Antibody

F47084-0.08ML 0.08 ml
EUR 140.25
Description: This gene encodes a member of the epidermal growth factor superfamily. The encoded protein is synthesized as a large precursor molecule that is proteolytically cleaved to generate the 53-amino acid epidermal growth factor peptide. This protein acts a potent mitogenic factor that plays an important role in the growth, proliferation and differentiation of numerous cell types. This protein acts by binding the high affinity cell surface receptor, epidermal growth factor receptor. Defects in this gene are the cause of hypomagnesemia type 4. Dysregulation of this gene has been associated with the growth and progression of certain cancers. Alternate splicing results in multiple transcript variants.

EGF Antibody

F47084-0.4ML 0.4 ml
EUR 322.15
Description: This gene encodes a member of the epidermal growth factor superfamily. The encoded protein is synthesized as a large precursor molecule that is proteolytically cleaved to generate the 53-amino acid epidermal growth factor peptide. This protein acts a potent mitogenic factor that plays an important role in the growth, proliferation and differentiation of numerous cell types. This protein acts by binding the high affinity cell surface receptor, epidermal growth factor receptor. Defects in this gene are the cause of hypomagnesemia type 4. Dysregulation of this gene has been associated with the growth and progression of certain cancers. Alternate splicing results in multiple transcript variants.

EGF Antibody

R36053-100UG 100 ug
EUR 339.15
Description: Additional name(s) for this target protein: Epidermal growth factor

EGF Antibody

R30469 100 ug
EUR 356.15
Description: Epidermal growth factor(EGF) is a growth factor that plays an important role in the regulation of cell growth, proliferation and differentiation by binding to its receptor EGFR. EGF locus is mapped to 4q21-4qter. Human EGF is a 6045-Da protein with 53 amino acid residues and three intramolecular disulfide bones. EGF results in cellular proliferation, differentiation, and survival while plays an important physiological role in the maintenance of oro-esophageal and gastric tissue integrity.

EGF Antibody

R31863 100 ug
EUR 356.15
Description: EGF is known as epidermal growth factor. This gene encodes a member of the epidermal growth factor superfamily. The encoded preproprotein is proteolytically processed to generate the 53-amino acid epidermal growth factor peptide. This protein acts a potent mitogenic factor that plays an important role in the growth, proliferation and differentiation of numerous cell types. Additionally, it acts by binding with high affinity to the cell surface receptor, epidermal growth factor receptor. Defects in this gene are the cause of hypomagnesemia type 4. Dysregulation of this gene has been associated with the growth and progression of certain cancers. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed.

EGF Antibody

R31864 100 ug
EUR 356.15
Description: EGF is known as epidermal growth factor. This gene encodes a member of the epidermal growth factor superfamily. The encoded preproprotein is proteolytically processed to generate the 53-amino acid epidermal growth factor peptide. This protein acts a potent mitogenic factor that plays an important role in the growth, proliferation and differentiation of numerous cell types. Additionally, it acts by binding with high affinity to the cell surface receptor, epidermal growth factor receptor. Defects in this gene are the cause of hypomagnesemia type 4. Dysregulation of this gene has been associated with the growth and progression of certain cancers. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed.

EGF Antibody

E92720 100ul
EUR 255
Description: Available in various conjugation types.

EGF Antibody

E38PA5289 100ul
EUR 225
Description: Available in various conjugation types.

EGF Antibody

AF5148-100ul 100ul
EUR 280

EGF Antibody

AF5148-200ul 200ul
EUR 350

EGF Antibody

AF5148 100ul
EUR 280
Description: Human,Mouse,Rat

EGF Antibody

E10-20414 100μg/100μl
EUR 225
Description: Available in various conjugation types.

EGF Antibody

E10-30015 100μg/100μl
EUR 225
Description: Available in various conjugation types.

EGF Antibody

E035720 100μg/100μl
EUR 255
Description: Available in various conjugation types.

EGF Antibody

E19-7063 100μg/100μl
EUR 225
Description: Available in various conjugation types.

EGF Antibody

E18-5148-1 50μg/50μl
EUR 145
Description: Available in various conjugation types.

EGF Antibody

E18-5148-2 100μg/100μl
EUR 225
Description: Available in various conjugation types.

EGF Antibody

E300887 200ul
EUR 275
Description: Available in various conjugation types.

egf Antibody

CAC11577-100ug 100ug
EUR 314

egf Antibody

CAC11577-50ug 50ug
EUR 199.2

EGF (1-51)

cyt-1115 100µg
EUR 80
Description: Recombinant Human Epidermal Growth Factor (1-51 a.a.)

HB-EGF/ Rat HB- EGF ELISA Kit

ELA-E1479r 96 Tests
EUR 1063.2

EGF GMP, CF

PR15112CF 200 ug
EUR 481.2

EGF, (Leu 21)

cyt-466 20µg
EUR 60
Description: Recombinant Human Epidermal Growth Factor 21-Leu

EGF (His tag)

EGPS009-10 10μg
EUR 30

EGF (His tag)

EGPS009-50 50μg
EUR 70

rHu EGF (cGMP)

AK9797-0040 40ug Ask for price

rec EGF (human)

H-7490.0100 0.1mg
EUR 194.4
Description: Sum Formula: C270H395N73O83S7; CAS# [62253-63-8]

rec EGF (human)

H-7490.0500 0.5mg
EUR 457.2
Description: Sum Formula: C270H395N73O83S7; CAS# [62253-63-8]

EGF Mouse mAb

E2220372 100ul
EUR 225
Description: Available in various conjugation types.

EGF Mouse mAb

E2220389 100ul
EUR 225
Description: Available in various conjugation types.

EGF Rabbit pAb

A12916-100ul 100 ul
EUR 369.6

EGF Rabbit pAb

A12916-200ul 200 ul
EUR 550.8

EGF Rabbit pAb

A12916-20ul 20 ul
EUR 219.6

EGF Rabbit pAb

A12916-50ul 50 ul
EUR 267.6

EGF Rabbit pAb

A13615-100ul 100 ul
EUR 369.6

EGF Rabbit pAb

A13615-200ul 200 ul
EUR 550.8

EGF Rabbit pAb

A13615-20ul 20 ul
EUR 219.6

EGF Rabbit pAb

A13615-50ul 50 ul
EUR 267.6

EGF Rabbit pAb

A2720-100ul 100 ul
EUR 369.6

EGF Rabbit pAb

A2720-200ul 200 ul
EUR 550.8

EGF Rabbit pAb

A2720-20ul 20 ul
EUR 219.6

EGF Rabbit pAb

A2720-50ul 50 ul
EUR 267.6

EGF Rabbit pAb

E2502720 100ul
EUR 225
Description: Available in various conjugation types.

EGF Rabbit pAb

E2513615 100ul
EUR 225
Description: Available in various conjugation types.

EGF Rabbit pAb

E2381803 100ul
EUR 225
Description: Available in various conjugation types.

EGF Rabbit pAb

E2251575 100ul
EUR 225
Description: Available in various conjugation types.

EGF Protein (OVA)

20-abx165531
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

HB EGF Antibody

DF13666-100ul 100ul
EUR 280

HB EGF Antibody

DF13666-200ul 200ul
EUR 350

Rat EGF protein

PRP1211-100ug 100 μg
EUR 149
Description: Rat EGF protein, expressed in E. coli

Rat EGF protein

PRP1211-1mg 1 mg
EUR 889
Description: Rat EGF protein, expressed in E. coli

Rat EGF protein

PRP1211-20ug 20 μg
EUR 59
Description: Rat EGF protein, expressed in E. coli

Rat EGF protein

PRP1211-500ug 500 μg
EUR 589
Description: Rat EGF protein, expressed in E. coli

In the present day, using synthetic intelligence for supporting this transition exhibits actual limitations in its implementation in operational follow, each on the stage of affected person care, but in addition within the basic each day lifetime of the well being skilled, due to the medico-legal imperatives induced by the guarantees of the ‘5P medication’.

On this paper, we suggest to fill this hole by introducing an authentic synthetic intelligence platform, named Maxwell, which follows an unsupervised studying method consistent with the medico-legal imperatives of the ‘5P medication’. We describe the useful platform traits and illustrate them by two examples of clustering in genomics and magnetic resonance imaging.